TIGECYCLINE

Tetracycline Antibiotic

Brand names: Tigecycline

Intravenous

Mechanism of Action

12.1 Mechanism of Action Tigecycline is a tetracycline class antibacterial [see Microbiology ( 12.4 )] .

Indications

including ventilator-associated pneumonia ( 1.4 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs

Enterococcus faecalis (vancomycin-susceptible isolates)

Staphylococcus aureus (methicillin-susceptible and -resistant isolates)

Streptococcus agalactiae

Streptococcus anginosus grp. (includes S. anginosus

S. intermedius

FDA Warnings

5 WARNINGS AND PRECAUTIONS All-Cause Mortality: A meta-analysis of Phase 3 and 4 clinical trials demonstrated an increase in all-cause mortality in tigecycline-treated patients compared to controls with a risk difference of 0
Patients who develop abnormal liver function tests during tigecycline for injection therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy
4 ) Pancreatitis: including fatalities, has been reported with tigecycline for injection
In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4% (150/3,788) of patients receiving tigecycline for injection and 3% (110/3,646) of patients receiving comparator drugs

Known Side Effects

5 documented side effects by frequency

Drug Not Working

>10%

Nausea

1-10%

Vomiting

1-10%

Diarrhea

0.1-1%

Condition Worsened

0.1-1%

Community Discussions

No community discussions found for TIGECYCLINE yet.

Compare With

7 available comparisons

Formulations

Dosage Forms

Tablet

Route

Intravenous